The evolution of allergen‐specific immunotherapy: The near and far future

Pajno, Giovanni Battista; Passanisi, Stefano; Valenzise, Mariella; Messina, Maria Francesca; Lombardo, Fortunato

doi:10.1111/pai.13351

Cited by 6 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The management of FA during the last 3 years was influenced by the COVID‐19 pandemic 157–160 with a shift to telemedicine 161 which will continue to influence practice. OIT has continued to gain momentum as an alternative to food avoidance in the management of FA.…”

Section: Updates On Clinical Treatment Approachesmentioning

confidence: 99%

An update on recent developments and highlights in food allergy

Locke

Hung

Upton

et al. 2023

Allergy

View full text Add to dashboard Cite

While both the incidence and general awareness of food allergies is increasing, the variety and clinical availability of therapeutics remain limited. Therefore, investigations into the potential factors contributing to the development of food allergy (FA) and the mechanisms of natural tolerance or induced desensitization are required. In addition, a detailed understanding of the pathophysiology of food allergies is needed to generate compelling, enduring, and safe treatment options. New findings regarding the contribution of barrier function, the effect of emollient interventions, mechanisms of allergen recognition, and the contributions of specific immune cell subsets through rodent models and human clinical studies provide novel insights. With the first approved treatment for peanut allergy, the clinical management of FA is evolving toward less intensive, alternative approaches involving fixed doses, lower maintenance dose targets, coadministration of biologicals, adjuvants, and tolerance‐inducing formulations. The ultimate goal is to improve immunotherapy and develop precision‐based medicine via risk phenotyping allowing optimal treatment for each food‐allergic patient.

show abstract

Section: Updates On Clinical Treatment Approachesmentioning

confidence: 99%

An update on recent developments and highlights in food allergy

Locke

Hung

Upton

et al. 2023

Allergy

View full text Add to dashboard Cite

show abstract

“…12 There is no curative treatment for IMDs apart from some allergies, where allergen desensitization treatment can lead to the loss of symptoms. 13,14 Other available treatments can alleviate symptoms but they cannot cure the disease or prevent completely long-term complications-moreover, there are significant costs and side effects of modern IMD therapies. Therefore, there is an unmet need to prevent IMDs or alleviate their symptoms with better approaches.…”

Section: What This Study Addsmentioning

confidence: 99%

Exposomic determinants of immune-mediated diseases

Laiho

Laitinen

Malkamäki

et al. 2022

Environmental Epidemiology

View full text Add to dashboard Cite

The incidence of immune-mediated diseases (IMDs) is increasing rapidly in the developed countries constituting a huge medical, economic, and societal challenge. The exposome plays an important role since genetic factors cannot explain such a rapid change. In the Human Exposomic Determinants of Immune Mediated Diseases (HEDIMED) project, altogether 22 academic and industrial partners join their multidisciplinary forces to identify exposomic determinants that are driving the IMD epidemic. The project is based on a combination of data and biological samples from large clinical cohorts constituting about 350,000 pregnant women, 30,000 children prospectively followed from birth, and 7,000 children from cross-sectional studies. HEDIMED focuses on common chronic IMDs that cause a significant disease burden, including type 1 diabetes, celiac disease, allergy, and asthma. Exposomic disease determinants and the underlying biological pathways will be identified by an exploratory approach using advanced omics and multiplex technologies combined with cutting-edge data mining technologies. Emphasis is put on fetal and childhood exposome since the IMD disease processes start early. Inclusion of several IMDs makes it possible to identify common exposomic determinants for the diseases, thus facilitating the development of widely operating preventive and curative treatments. HEDIMED includes data and samples from birth cohorts and clinical trials that have used exposomic interventions and cell and organ culture models to identify mechanisms of the observed associations. Importantly, HEDIMED generates a toolbox that offers science-based functional tools for key stakeholders to control the IMD epidemic. Altogether, HEDIMED aims at innovations, which become widely exploited in diagnostic, therapeutic, preventive, and health economic approaches.

show abstract

“…Indeed, allergen immunotherapy is currently introduced into clinical practice and it is accepted worldwide [ 65 , 66 ]. However, there are still many unknown aspects which have to be resolved such as the achievement of persistent tolerance [ 67 ] and others related to management. In addition, the current coronavirus pandemic (COVID-19) situation must be taken into account, and some reports advise discontinuation of immunotherapy in children infected with severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2), because intercurrent viral infections could act as triggers of mild adverse effects or systemic allergic reactions [ 68 ].…”

Section: Allergen-specific Treatmentsmentioning

confidence: 99%

New Insights in Therapy for Food Allergy

Mayorga

Palomares

Cañas

et al. 2021

Foods

View full text Add to dashboard Cite

Food allergy is an increasing problem worldwide, with strict avoidance being classically the only available reliable treatment. The main objective of this review is to cover the latest information about the tools available for the diagnosis and treatment of food allergies. In recent years, many efforts have been made to better understand the humoral and cellular mechanisms involved in food allergy and to improve the strategies for diagnosis and treatment. This review illustrates IgE-mediated food hypersensitivity and provides a current description of the diagnostic strategies and advances in different treatments. Specific immunotherapy, including different routes of administration and new therapeutic approaches, such as hypoallergens and nanoparticles, are discussed in detail. Other treatments, such as biologics and microbiota, are also described. Therefore, we conclude that although important efforts have been made in improving therapies for food allergies, including innovative approaches mainly focusing on efficacy and safety, there is an urgent need to develop a set of basic and clinical results to help in the diagnosis and treatment of food allergies.

show abstract

The evolution of allergen‐specific immunotherapy: The near and far future

Abstract: In the era of precision medicine, allergen immunotherapy (AIT) represents a landmark for the management of IgE-mediated allergic diseases. AIT is recognized as a potentially curative therapy and is currently accepted and routinely prescribed worldwide.

Cited by 6 publications

References 10 publications

An update on recent developments and highlights in food allergy

An update on recent developments and highlights in food allergy

Exposomic determinants of immune-mediated diseases

New Insights in Therapy for Food Allergy

Contact Info

Product

Resources

About